Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer
Pharmaceutics · 05.08.2023 · 15 (8) · 2090
DOI: 10.3390/pharmaceutics15082090 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 05.08.2023. Verfasst von Zaid Sirhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Elsa U. Pardee Foundation, National Institute of Health.
Abstract (Originalsprache)
Lung cancer remains one of the major human malignancies affecting both men and women worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent type. Multiple mechanisms have been identified that favor tumor growth as well as impede the efficacy of therapeutic regimens in lung cancer patients. Among tumor suppressor genes that play critical roles in regulating cancer growth, the phosphatase and tensin homolog (PTEN) constitutes one of the important family members implicated in controlling various functional activities of tumor cells, including cell proliferation, apoptosis, angiogenesis, and metastasis. Notably, clinical studies have also documented that lung tumors having an impaired, mutated, or loss of PTEN are associated with low survival or high tumor recurrence rates. To that end, PTEN has been explored as a promising target for anti-cancer agents. Importantly, the ability of PTEN to crosstalk with several signaling pathways provides new approaches to devise effective treatment options for lung cancer treatment. The current review highlights the significance of PTEN and its implications in therapeutic approaches against NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.
Förderung
- NIEHS NIH HHS
- Elsa U. Pardee Foundation
- National Institute of Health
- NIH R21
Zitieren
APA
Sirhan, Z., Alojair, R., Thyagarajan, A., & Sahu, R. P. (2023). Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer. Pharmaceutics, 15(8), 2090. https://doi.org/10.3390/pharmaceutics15082090
Vancouver
Sirhan Z, Alojair R, Thyagarajan A, Sahu RP. Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer. Pharmaceutics. 2023;15(8):2090. doi:10.3390/pharmaceutics15082090
BibTeX
@article{Sirhan2023,
author = {Sirhan, Zaid and Alojair, Rawan and Thyagarajan, Anita and Sahu, Ravi P},
title = {Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {8},
pages = {2090},
doi = {10.3390/pharmaceutics15082090}
}
EUVIMED